Minesh Patel, MD
Hematology & Oncology · Newnan, GANPI 1699094300
Payments from drug & device makers
Across 121 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$376
- AbbVie$262
- Bayer$184
- Genentech USA, Inc.$151
- Merck$109
- Pfizer$99
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,35596%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $376 |
| AbbVie | 12 | $262 |
| Bayer | 10 | $184 |
| Genentech USA, Inc. | 9 | $151 |
| Merck | 6 | $109 |
| Pfizer | 5 | $99 |
| Beigene USA, Inc. | 4 | $93 |
| Johnson & Johnson | 6 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Eisai Inc. | 5 | $83 |
| Sobi, Inc | 1 | $70 |
| Taiho Oncology, Inc. | 2 | $69 |
| Astellas Pharma US Inc | 3 | $69 |
| Stemline Therapeutics Inc. | 3 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $56 |
| Gilead(2 entities) | 4 | $54 |
| Seagen Inc. | 3 | $47 |
| Sanofi | 2 | $47 |
| AstraZeneca(2 entities) | 2 | $45 |
| Amgen | 3 | $43 |
| Springworks Therapeutics, Inc. | 2 | $41 |
| Mckesson Specialty Care Distribution, LLC | 1 | $29 |
| Beone Medicines USA, Inc. | 1 | $25 |
| CSL Behring | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Octapharma USA, Inc. | 1 | $12 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
How this compares
$2,454 in reported general payments places this provider in the 30th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 191 | $2,716,397 |
| VenclextaVenetoclax | 69 | $837,637 |
| BrukinsaZanubrutinib | 36 | $538,728 |
| XtandiEnzalutamide | 36 | $491,334 |
| ImbruvicaIbrutinib | 31 | $485,898 |
| CabometyxCabozantinib S-Malate | 18 | $463,699 |
| PomalystPomalidomide | 19 | $433,517 |
| InlytaAxitinib | 20 | $367,485 |
| KisqaliRibociclib Succinate | 19 | $362,575 |
| CalquenceAcalabrutinib Maleate | 26 | $350,240 |
| VerzenioAbemaciclib | 24 | $347,417 |
| Abiraterone Acetate | 128 | $316,441 |
| IbrancePalbociclib | 17 | $274,494 |
| Udenyca AutoinjectorPegfilgrastim-Cbqv | 69 | $273,191 |
| Lupron DepotLeuprolide Acetate | 48 | $240,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta, Lupron Depot | $262 | $1,077,722117 claims |
| PfizerInlyta, Ibrance, Eliquis | $99 | $814,789224 claims |
| Beigene USA, Inc.Brukinsa | $93 | $538,72836 claims |
| Astellas Pharma US IncXtandi | $69 | $491,33436 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $56 | $485,89831 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $17 | $433,51719 claims |
| NovartisKisqali | $376 | $362,57519 claims |
| AstraZenecaCalquence | $45 | $350,24026 claims |
| Lilly USA, LLCVerzenio | $13 | $347,41724 claims |
| AmgenNeulasta, Xgeva | $43 | $107,66323 claims |
| Johnson & JohnsonXarelto, Procrit | $92 | $83,12554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Newnan
- Vasileios AssikisNewnan$3.1M
- Nitika SharmaNewnan$411K
- Bamidele AdesunloyeNewnan$343K
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.